{"disease":{"id":"neuroendocrine-carcinomas-of-pancreas","name":"neuroendocrine carcinomas of pancreas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06893783","title":"Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Inkeun Park","has_results":false},{"nct_id":"NCT03042780","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}